116 related articles for article (PubMed ID: 25474525)
1. Active surveillance for prostate cancer: the role of the pathologist.
Delahunt B; Hammond E; Egevad L; Samaratunga H; Srigley JR; Humphrey PA; Rubin M; Epstein JI; Lin DW; Gore JL; Nacey JN; Klotz L; Sandler H; Zietman AL; Holden S; Montironi R; Evans AJ; McKenney JK; Berney D; Wheeler TM; Chinnaiyan AM; True L; Knudsen B; Amin MB
Pathology; 2015 Jan; 47(1):1-3. PubMed ID: 25474525
[No Abstract] [Full Text] [Related]
2. Active surveillance for early-stage prostate cancer.
Lancet; 2014 Jan; 383(9913):188. PubMed ID: 24439724
[No Abstract] [Full Text] [Related]
3. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
Carlsson S; Vickers AJ; Roobol M; Eastham J; Scardino P; Lilja H; Hugosson J
J Clin Oncol; 2012 Jul; 30(21):2581-4. PubMed ID: 22711853
[No Abstract] [Full Text] [Related]
4. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
Cooperberg MR; Lin DW; Morgan TM; Chapin BF; Chen RC; Eggener SE
J Urol; 2022 Feb; 207(2):262-264. PubMed ID: 34775795
[No Abstract] [Full Text] [Related]
5. [Overdiagnosis in prostate cancer].
Villeda C; Gomez MO; Sotomayor M
Arch Esp Urol; 2014 Jun; 67(5):388-92. PubMed ID: 24914837
[TBL] [Abstract][Full Text] [Related]
6. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
7. PSA screening: the USPSTF got it wrong.
Scherger JE
J Fam Pract; 2013 Nov; 62(11):616, 618. PubMed ID: 24288701
[No Abstract] [Full Text] [Related]
8. Screening and active surveillance in prostate cancer: the dilemma continues.
Hamdy FC; Albertsen PC; Donovan JL
BJU Int; 2024 Jul; 134(1):1-2. PubMed ID: 38514989
[No Abstract] [Full Text] [Related]
9. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
10. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance monitoring more stringent in updated NCCN Guidelines for prostate cancer.
J Natl Compr Canc Netw; 2011 May; 9(5):xxxvii-xlii. PubMed ID: 21739727
[No Abstract] [Full Text] [Related]
13. Active surveillance in all cases of screen-detected prostate cancer.
Takahashi T
BJU Int; 2024 Jul; 134(1):136. PubMed ID: 38504623
[No Abstract] [Full Text] [Related]
14. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer.
Gorin MA; Soloway CT; Eldefrawy A; Soloway MS
Urology; 2011 Mar; 77(3):588-91. PubMed ID: 21215429
[TBL] [Abstract][Full Text] [Related]
15. The Prostate cancer Research International: Active Surveillance study.
Bangma CH; Bul M; Roobol M
Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance: the Canadian experience.
Klotz L
Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
[TBL] [Abstract][Full Text] [Related]
17. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
18. [Active surveillance in prostate cancer. Introduction].
Briones JR
Arch Esp Urol; 2014 Jun; 67(5):367-8. PubMed ID: 25039087
[No Abstract] [Full Text] [Related]
19. The role of 5-alpha-reductase inhibitors in active surveillance.
Margel D; Fleshner N
Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
[TBL] [Abstract][Full Text] [Related]
20. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Bartoletti R; Cai T
Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
[No Abstract] [Full Text] [Related]
[Next] [New Search]
